<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164768">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839097</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-BEL-12-104</org_study_id>
    <nct_id>NCT01839097</nct_id>
  </id_info>
  <brief_title>Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)</brief_title>
  <official_title>Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for
      belinostat when combined with CHOP regimen and establish the recommended belinostat dose for
      the Phase 3 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to
      evaluate the Maximum Tolerated Dose (MTD) of belinostat when administered in combination
      with CHOP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>up to 5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the MTD for belinostat when combined with CHOP regimen and establish the Phase 3 recommended belinostat dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>up to 5 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess safety and tolerance of belinostat when given in combination with CHOP regimen. Safety and tolerance will be mainly characterized by the number and severity of treatment emergent adverse events, and treatment related AEs that occur or worsen after the first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>126 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall response rate (ORR) after 6 cycles of BelCHOP regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of study drug</measure>
    <time_frame>126 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pharmacokinetics of belinostat when co-administered with CHOP regimen. The concentration of Belinostat to assess the effectiveness.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dose Finding Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.
Enrollment will begin with the enrollment of patients into Cohort 3.
On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat</intervention_name>
    <description>Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:
Cohort 1: belinostat 1000 mg/m2 IV on Day 1
Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2
Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3
Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4
Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5</description>
    <arm_group_label>Dose Finding Phase</arm_group_label>
    <other_name>PXD101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP</intervention_name>
    <description>Cyclophosphamide - 750 mg/m2 - IV - Day 1
Vincristine - 1.4 mg/m2 - IV - Day 1
Doxorubicin - 50mg/m2 - IV - Day 1
Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat.</description>
    <arm_group_label>Dose Finding Phase</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Vincristine</other_name>
    <other_name>Doxorubicin</other_name>
    <other_name>Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or above

          -  Life Expectancy &gt; 3 months

          -  Histologically confirmed diagnosis of PTCL

          -  Patients with transformed CTCL eligible for CHOP regimen

          -  Measurable disease based on Cheson 2007 criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2

        Exclusion Criteria:

          -  Known active Hepatitis B/ Hepatitis C/ HIV infection

          -  Known, uncontrolled CNS metastases or primary CNS lymphoma

          -  Deep vein thrombosis diagnosed within 3 months

          -  Ongoing treatment for pre-existing cardiovascular disease

          -  Neuropathy Grade 3 or more

          -  Previous extensive radiotherapy except limited field RT for locally advanced   nasal
             NK PTCL or for pain palliation

          -  Prior therapy with severely myelotoxic regimens, including autologous and
             allogenic stem cell transplantation

          -  Prior therapy with HDAC inhibitors (except for CTCL)

          -  Inadequate hematological, hepatic, or renal function
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mi Rim Choi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Le</last_name>
    <phone>214-504-1938</phone>
    <email>william.le@sppirx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmngham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Hamby, RN, BSN, OCN</last_name>
      <phone>205-934-0314</phone>
      <email>bhamby@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Naresh Bellam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Cancer Care, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson, CCRC</last_name>
      <phone>706-353-2990</phone>
      <email>jhodgson@negacancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Amundson</last_name>
      <phone>507-293-1933</phone>
      <email>Amundson.michelle@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick B Johnston, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Larson</last_name>
      <phone>314-362-3257</phone>
      <email>salarson@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Cashen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Valentinetti, RN</last_name>
      <phone>551-996-5900</phone>
      <email>MValentinetti@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology - Oncology Associates of Northern NJ P.A</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie, RN</last_name>
      <phone>973-538-3593</phone>
      <email>mmackenzie@hoannj.com</email>
    </contact>
    <investigator>
      <last_name>Charles M Farber, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/Center for Lymphiod Malignancies</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Wright</last_name>
      <phone>212-326-5731</phone>
      <email>Dw2316@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jasmine Zain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Alton</last_name>
      <phone>919-681-4769</phone>
      <email>Peggy.alton@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Beaven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTCL</keyword>
  <keyword>Maximum Tolerated Dose</keyword>
  <keyword>Belinostat</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
